Biovie Net Worth
Biovie Net Worth Breakdown | BIVI |
Biovie Net Worth Analysis
Biovie's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biovie's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biovie's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biovie's net worth analysis. One common approach is to calculate Biovie's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biovie's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biovie's net worth. This approach calculates the present value of Biovie's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biovie's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biovie's net worth. This involves comparing Biovie's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biovie's net worth relative to its peers.
To determine if Biovie is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biovie's net worth research are outlined below:
| Biovie Inc is way too risky over 90 days horizon | |
| Biovie Inc appears to be risky and price may revert if volatility continues | |
| Biovie Inc has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (32.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biovie Inc currently holds about 18.64 M in cash with (27.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Biovie Inc has a frail financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID ... |
Biovie Quarterly Good Will |
|
Biovie uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biovie Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biovie's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of August 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Know Biovie's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biovie is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biovie Inc backward and forwards among themselves. Biovie's institutional investor refers to the entity that pools money to purchase Biovie's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cwm, Llc Duplicate | 2024-06-30 | 215 | Goss Wealth Management Llc | 2024-09-30 | 100.0 | Flaharty Asset Management, Llc | 2024-09-30 | 100.0 | Jpmorgan Chase & Co | 2024-09-30 | 77.0 | Financial Perspectives Inc | 2024-09-30 | 59.0 | Ubs Group Ag | 2024-09-30 | 45.0 | New York State Common Retirement Fund | 2024-06-30 | 35.0 | Harbour Investments, Inc. | 2024-09-30 | 30.0 | Jaffetilchin Investment Partners, Llc | 2024-09-30 | 21.0 | Vanguard Group Inc | 2024-09-30 | 56.8 K | Geode Capital Management, Llc | 2024-09-30 | 38.2 K |
Follow Biovie's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 55.08 M.Market Cap |
|
Project Biovie's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (2.03) | (2.13) | |
| Return On Assets | (1.27) | (1.34) | |
| Return On Equity | (2.07) | (2.18) |
When accessing Biovie's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biovie's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biovie's profitability and make more informed investment decisions.
Evaluate Biovie's management efficiency
Biovie Inc has return on total asset (ROA) of (0.6669) % which means that it has lost $0.6669 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0826) %, meaning that it created substantial loss on money invested by shareholders. Biovie's management efficiency ratios could be used to measure how well Biovie manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.38. The current Return On Capital Employed is estimated to decrease to -2.13. As of now, Biovie's Non Current Assets Total are increasing as compared to previous years. The Biovie's current Other Assets is estimated to increase to 5,509, while Non Currrent Assets Other are projected to decrease to 0.00.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.43 | 3.72 | |
| Tangible Book Value Per Share | 3.26 | 3.43 | |
| Enterprise Value Over EBITDA | (0.03) | (0.03) | |
| Price Book Value Ratio | 1.22 | 1.15 | |
| Enterprise Value Multiple | (0.03) | (0.03) | |
| Price Fair Value | 1.22 | 1.15 | |
| Enterprise Value | 998.9 K | 887.9 K |
The leadership approach at Biovie's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Return On Equity (2.08) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biovie insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biovie's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biovie insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biovie Corporate Filings
| 2nd of December 2024 Other Reports | ViewVerify | |
| 27th of November 2024 Other Reports | ViewVerify | |
| 22nd of November 2024 Other Reports | ViewVerify | |
S1 | 21st of November 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Biovie Earnings per Share Projection vs Actual
Biovie Corporate Management
| Joseph MD | Executive Officer | Profile | |
| Clarence Ahlem | Senior Operations | Profile | |
| Joanne CPA | Treasurer CFO | Profile | |
| Denise Smith | Senior Development | Profile | |
| Sarah Hoit | Chief Officer | Profile | |
| MBA MBA | CEO Pres | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biovie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biovie. If investors know Biovie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biovie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.08) | Return On Assets (0.67) | Return On Equity (2.08) |
The market value of Biovie Inc is measured differently than its book value, which is the value of Biovie that is recorded on the company's balance sheet. Investors also form their own opinion of Biovie's value that differs from its market value or its book value, called intrinsic value, which is Biovie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biovie's market value can be influenced by many factors that don't directly affect Biovie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biovie's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biovie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biovie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.